儿科口腔角膜炎的辅助疗法:关于微生物清除和治疗坚持的前性受控研究
Alexandru-Emilian Flondor1, Irina-Georgeta Sufaru1, Maria-Alexandra Martu1
1Faculty of Dental Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Children (Basel, Switzerland)
|November 27, 2025
概括
在标准的抗真菌治疗中添加阿洛韦拉凝改善了口腔候群症儿童的真菌清除和坚持. 这表明,可能是儿童真菌感染的有益补充疗法.
科学领域:
- 儿童传染病 儿童传染病
- 菌类学 菌类学是指菌类学.
- 皮肤病学 皮肤病学
背景情况:
- 口腔角膜炎在婴儿和幼儿中很常见.
- 标准的抗真菌疗法面临着坚持和复发的挑战.
- 花具有抗微生物和治疗性质.
研究的目的:
- 评估局部叶凝对中度口腔候群症儿童的真菌负荷和治疗坚持的辅助作用.
- 评估阿洛韦拉添加到标准抗真菌疗法的影响.
主要方法:
- 对54名儿童进行前性对照研究.
- 随机分配单独使用尼斯塔丁或尼斯塔丁与叶凝7天.
- 用殖民地形成单位 (CFU) 评估真菌负荷,也测量了粘附和复发.
主要成果:
- 阿洛韦拉组在第7天显示出更大的真菌负荷减少.
- 在阿洛韦拉群体中,治疗坚持程度明显高 (92.73% vs 89.21%).
- 基线真菌负担和坚持与复发风险有关.
结论:
- 局部使用的阿洛韦拉凝可以增强儿科口服候群病的真菌清除和坚持.
- 花显示出作为补充治疗口腔真菌感染的潜力.
- 这些发现是初步的;需要进行更大规模的研究来确认疗效和复发率.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Peptic Ulcer Disease IV: Management
407
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
407
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Tonsillitis II: Management
387
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
387
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435


